IPSEN PHARMA

In News

Ipsen shares soar on stellar results - The Pharma Letter

The Pharma Letter - Feb 12, 2026

FY 2025: Strong results and momentum for 2026 - Ipsen

Ipsen - Feb 12, 2026

Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital - Yahoo Finance UK

Yahoo Finance UK - Feb 09, 2026

Ipsen writes check worth up to €1B to acquire next-gen cancer biotech - Fierce Biotech

Fierce Biotech - Oct 22, 2025

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance - The Globe and Mail

The Globe and Mail - Feb 12, 2026

Ipsen Chief Calls On Europe To Improve Access - Citeline News & Insights

Citeline News & Insights - Feb 13, 2026

Genfit adds $20M as Ipsen records strong sales for liver drug - Seeking Alpha

Seeking Alpha - Feb 12, 2026

Ipsen selects Pierrick Lefranc as new EVP Technical Operations - European Pharmaceutical Review

European Pharmaceutical Review - Jan 27, 2026

Ipsen buys ImCheck, adding mid-stage leukaemia drug - pharmaphorum

pharmaphorum - Oct 22, 2025

Therapeutic focus - Ipsen

Ipsen - Oct 15, 2025

Ipsen nominates Peter Guenter to its Board of Directors - Yahoo Finance

Yahoo Finance - Jan 28, 2026

Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail - Fierce Biotech

Fierce Biotech - Dec 19, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment